Literature DB >> 21592781

Levels of acute health service use among cancer survivors in the United Kingdom.

Jacob Maddams1, Martin Utley, Henrik Møller.   

Abstract

BACKGROUND: In the United Kingdom, there are approximately two million cancer survivors (3.2% of the entire population), composed of groups of people in different phases of survivorship and with different health service needs. The aim of this study was to quantify the level of acute health service utilisation by cancer survivors in the UK, according to tumour type, age, sex, time since diagnosis, and time until death.
METHODS: Linked national cancer registry and hospital activity data were analysed. The data covered all cancer-related admissions to public hospitals operated by the National Health Service in England occurring in 2006 among people diagnosed with cancer in the period 1990-2006. The intensity of cancer-related health service utilisation was categorised as 'none', 'low' (up to 10% of an individual's time), or 'high' (>10% of an individual's time), among groups defined by time since diagnosis and time until death. Results were extrapolated from the population of England in 2006 (51 million) to that of the UK in 2008 (61 million).
FINDINGS: Sixty one thousand of the two million cancer survivors (3%) were in the 'high' utilisation category; 240,000 (12%) were in the 'low' category; 1.70 million (85%) had no cancer-related hospital admissions. 147,000 cancer survivors (7%) were in the last year of their life, and it was this group that had the highest levels of hospital utilisation. 1.57 million cancer survivors (78%) were more than 1 year from both diagnosis and death, and had no cancer related hospital admissions.
INTERPRETATION: A considerable proportion of cancer survivors in the UK have a high level of hospital utilisation soon after diagnosis or before death, but the large majority of them are neither recently diagnosed nor near the end of their life, and do not utilise acute health services for cancer-related care.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21592781     DOI: 10.1016/j.ejca.2011.04.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs.

Authors:  Xue Qin Yu; Mark Clements; Dianne O'Connell
Journal:  J Cancer Surviv       Date:  2013-08-07       Impact factor: 4.442

2.  Projections of cancer prevalence in the United Kingdom, 2010-2040.

Authors:  J Maddams; M Utley; H Møller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

3.  A person-time analysis of hospital activity among cancer survivors in England.

Authors:  J Maddams; M Utley; H Møller
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

4.  The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors.

Authors:  M Richards; J Corner; J Maher
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

5.  New pathways of care for cancer survivors: adding the numbers.

Authors:  J Maher; H McConnell
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

6.  What are colorectal cancer survivors' preferences for dietary advice? A best-worst discrete choice experiment.

Authors:  Stuart J Wright; Debbie Gibson; Martin Eden; Simon Lal; Chris Todd; Andy Ness; Sorrel Burden
Journal:  J Cancer Surviv       Date:  2017-04-20       Impact factor: 4.442

7.  Conventional health care service utilization among cancer survivors that visit traditional and complementary providers in the Tromsø study: a cross-sectional study.

Authors:  Kiwumulo Nakandi; Dana Mora; Trine Stub; Agnete E Kristoffersen
Journal:  BMC Health Serv Res       Date:  2022-01-11       Impact factor: 2.655

8.  Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study.

Authors:  Paolo Baili; Francesca Di Salvo; Francesco de Lorenzo; Francesco Maietta; Carmine Pinto; Vera Rizzotto; Massimo Vicentini; Paolo Giorgi Rossi; Rosario Tumino; Patrizia Concetta Rollo; Giovanna Tagliabue; Paolo Contiero; Pina Candela; Tiziana Scuderi; Elisabetta Iannelli; Stefano Cascinu; Fulvio Aurora; Roberto Agresti; Alberto Turco; Milena Sant; Elisabetta Meneghini; Andrea Micheli
Journal:  Support Care Cancer       Date:  2015-11-16       Impact factor: 3.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.